{Reference Type}: Journal Article
{Title}: Systematic review of clinical practice guidelines to identify recommendations for sleep in type 2 diabetes mellitus management.
{Author}: Smyth A;Jenkins M;Dunham M;Kutzer Y;Taheri S;Whitehead L;
{Journal}: Diabetes Res Clin Pract
{Volume}: 170
{Issue}: 0
{Year}: Dec 2020
{Factor}: 8.18
{DOI}: 10.1016/j.diabres.2020.108532
{Abstract}: BACKGROUND: Sleep quality, quantity and timing have been shown to impact glycaemic control, with a role in insulin sensitivity, glucose tolerance and HbA1C levels, in both diabetic and non-diabetic populations. The aim of this study was to identify recommendations for sleep assessment and management in international clinical practice guidelines focused on type 2 diabetes mellitus management in adults.
METHODS: Systematic Review.
METHODS: Clinical practice guidelines which focused on the management of type 2 diabetes mellitus in adults were included (n = 35). Two independent reviewers utilised the Appraisal of Guidelines for Research and Evaluation tool (AGREE) II and a third reviewer resolved any disagreements. Included guidelines were assessed for recommendations about sleep in diabetes management (n = 14). Data were extracted on sleep recommendations ,themes were generated from the extracted data and narrative syntheses were created.
RESULTS: From 1114 identified papers, 35 guidelines met the inclusion criteria. Fourteen of these guidelines included recommendations pertaining to sleep, which broadly fell into five categories; sleep assessment, sleep as a therapeutic target, sleep and co-morbidities of type 2 diabetes mellitus, shift work and sleep and driving. Recommendations varied across guidelines.
CONCLUSIONS: Few guidelines provided recommendations relating to assessment and management of sleep in type 2 diabetes care. Most of the recommendations were related to obstructive sleep apnoea. However, few guidelines discussed sleep as a therapeutic intervention for diabetes mellitus or described the potential importance of sleep quality and duration in glycaemic control. Prospero registration number: CRD42020142136.